Article
LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Biochemical and biophysical research communications - 27 Nov 2015
Wu Ying, Yu Dan-dan, Hu Yong, Cao Hai-xia, Yu Shao-rong, Liu Si-wen, Feng Ji-feng
Abstract excerpt
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Prolonged cancer treatment will induce the development of acquired resistance to EGFR TKI. Here we investigate the effects of two novel liver x receptor (LXR) ligands (T0901317 or GW3965) on the development of acquired resistance to an EGFR TKI gefitinib. We observed known...
Topics
- Adenocarcinoma
- Apoptosis
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Enzyme Activation
- ErbB Receptors
- Gefitinib
- Humans
- In Vitro Techniques
- Ligands
- Liver X Receptors
- Lung Neoplasms
- Mutation
- Orphan Nuclear Receptors